Browsing Category News

How Pharmaceutical Packaging Can Lead to Product Recalls

Pharmaceutical manufacturers generally pay close attention to ensure they are compliant with GMP standards and FDA regulations when manufacturing drug. But sometimes, the packaging of the pharmaceutical can be an afterthought. It is estimated that as many as 50% of drug recalls are because of errors with product labeling and artwork on the packaging. This [...]

Read More »

Category : News

Canada Has Completed Its Transition to MDSAP

Most of the medical device companies in the Canadian market were able to meet the deadline of Jan. 1 2019 to complete a transition to the Medical Device Single Audit Program or MDSAP. According to Health Canada’s Medical Devices Bureau, the organization was flooded early this year with the transition packages from many companies. The [...]

Read More »

Category : News

FDA Audit Shows Data Manipulation at Immunonedics Plant

Immunomedics received a complete response letter from FDA last month that related to cGMP issues in manufacturing regarding its breast cancer antibody drug conjugate. When they were pressed by pharma analysts, executives for the pharma company dodged questions about if it was related to a preapproval inspection last year. How to Survive Your Next FDA [...]

Read More »

Category : News

Why Do You Need a Quality Agreement?

A quality agreement provides precise details of what is expected from both parties and who will be responsible for all of the aspects of the pharmaceutical project. There is a misconception that a quality agreement is only needed for CMOs operating in a different type of regulatory environment. This is not the case. Any outsourcing  [...]

Read More »

Category : News

You Can’t Change That: FDA Reiterates Risk of Delegating Responsibility in Quality Agreements

In the span of three weeks, the Food and Drug Administration issued Warning Letters to two dietary supplement companies, in part, for relying, to their detriment, on quality agreements. We discussed another similar Warning Letter in a recent Bulletin. Regardless of the type of FDA-regulated product, the agency made clear that, despite an agreement, a [...]

Read More »

Category : News

You Can’t Pass the Regulatory Compliance Buck with a Quality Agreement; FDA Reiterates the Point in a Recent Warning Letter

Companies can’t sign quality agreements and then say “we’re done.” This message was brought home with a recent Warning Letter issued by the Food and Drug Administration to a pharmaceutical company for violating current good manufacturing practice requirements for combination products, drugs, and medical devices. The Warning Letter included a myriad of quality-related concerns, including inadequate [...]

Read More »

Category : News

Anyone Can Enter Into a Quality Agreement, It’s the Hold: FDA Issues a Warning Letter Referencing Lack of Quality Oversight

Many of us remember the classic comedy bit on the Seinfeld television show where Jerry was unable to secure the rental car for which he had made a reservation. He tells the agent: See, you know how to ‘take’ the reservation, you just don’t know how to ‘hold’ the reservation and that’s really the most [...]

Read More »

Category : News

Federal Judge Issues Consent Decree for OTC Tennessee Drug Manufacturer

A federal court has issued an order to an over the counter drug company in Tennessee to cease the sale of OTC products until such time it is compliant with the FD&C Act. According to CDER, Americans both deserve and expect high quality OTC drug products. Although the company in question was given several warnings, [...]

Read More »

Category : News

Catalent Fixes 483 Citations at Bloomington, Indiana Plant

The US Food and Drug Administration (FDA) recently published a Form 483 it issued to Catalent’s biomanufacturing facility in Bloomington, Indiana following an inspection in April and May this year. The Agency made five observations at the 875,000ft2 production and fill/finish facility, which the contract development and manufacturing organization (CDMO) gained as part of its $950 million [...]

Read More »

Category : News

FDA Corrects Import Ban for Embattled Valsartan Maker

After Zhejiang Huahai Pharmaceutical’s tainted valsartan API triggered a global recall, the FDA slapped an import ban on the drugmaker. But the agency made a confusing mistake in announcing the move—a mistake it just corrected. The FDA announced Sept. 28 that it had imposed an import alert banning “all” active pharmaceutical ingredients made by Huahai, [...]

Read More »

Category : News

Subscribe Now

Testimonial

"ExpertBriefings.com always selects excellent speakers – some of the best I have ever heard. Their messages are direct, clear, timely, and relevant."

Anon A. Mouse

Featured Partner